Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
44 participants
OBSERVATIONAL
1997-09-30
2004-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC)
NCT01482104
Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight
NCT01349361
Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate
NCT01491711
Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment
NCT02587819
Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy
NCT05020912
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* one or two PDT treatments with treatment interval no longer than two weeks.
* lesion complete response three months after therapy.
Exclusion Criteria
* Gorlin's syndrome.
* morpheaform or pigmented bcc.
* histology older than one year.
* tumour infiltration more than four mm.
* previous PDT treated lesions.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
St. Olavs Hospital
OTHER
Norwegian University of Science and Technology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eidi Christensen, MD
Role: PRINCIPAL_INVESTIGATOR
St. Olav University Hospital, Trondheim
References
Explore related publications, articles, or registry entries linked to this study.
Christensen E, Skogvoll E, Viset T, Warloe T, Sundstrom S. Photodynamic therapy with 5-aminolaevulinic acid, dimethylsulfoxide and curettage in basal cell carcinoma: a 6-year clinical and histological follow-up. J Eur Acad Dermatol Venereol. 2009 Jan;23(1):58-66. doi: 10.1111/j.1468-3083.2008.02946.x. Epub 2008 Sep 18.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EC-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.